Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

4.65EUR
15 Dec 2017
Change (% chg)

€-0.08 (-1.69%)
Prev Close
€4.73
Open
€4.75
Day's High
€4.75
Day's Low
€4.63
Volume
251,301
Avg. Vol
293,924
52-wk High
€15.83
52-wk Low
€4.33

Select another date:

Wed, Nov 22 2017

BRIEF-Innate Pharma provides an update on lirilumab

* ‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS

BRIEF-Innate Pharma Q3 revenue up at 12.4 million euros

* Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO

BRIEF-Innate Pharma reports IPH4102 final results of the dose-escalation part of the phase I study

* IPH4102: FINAL RESULTS OF THE DOSE-ESCALATION PART OF THE PHASE I STUDY

BRIEF-Innate Pharma H1 operating loss widens to 18.2 million euros

* ‍CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS() FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017​

BRIEF-New preclinical data further strengthen rationale of IPH5401 and Monalizumab

* REG-INNATE PHARMA : NEW PRECLINICAL DATA FURTHER STRENGTHEN THE RATIONALE OF IPH5401 AND MONALIZUMAB

BRIEF-Innate Pharma issues 3,343,748 ordinary shares

* REG-ISSUANCE BY INNATE PHARMA OF 3,343,748 ORDINARY SHARES TO NOVO NORDISK A/S IN CONSIDERATION FOR RIGHTS IN ANTI-C5AR

BRIEF-Innate Pharma to list 3,343,748 new ordinary shares - Euronext‍​

* INNATE PHARMA TO LIST 3,343,748 NEW ORDINARY SHARES AS OF JULY 17 FOLLOWING CAPITAL INCREASE BY CONTRIBUTION FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

Select another date: